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significant differences in results. Three studies have indicated no 
differences in in-vitro cell survival curves between standard and 
flattening filter free irradiations for a range of different cancer cell 
lines. One study suggested differences were present at high doses. In 
this presentation the potential radiobiological implications of 
Flattening Filter Free treatments will be explored and the current 
literature reviewed.  
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FFF beams are now available on medical accelerators for clinical use. 
Without flattening filter, the dose profiles are very different from 
conventional beams. It was necessary to establish new definitions of 
physical parameters such as symmetry, non-uniformity and penumbra. 
Various methods have been published. However, the filtered beams 
are used on the basis of geometric and dosimetric tolerances which 
have now to be redefined for these new FFF beams. 
The tolerances come from a compromise between what is technically 
feasible and what is clinically acceptable. 2% or 2mm are, for 
example, values that are easily translated to the effects on the dose 
profile and clinical irradiations. With FFF beams, amplitude profile 
differences no longer allow the same physical analysis and the impact 
of physical variations, necessarily modulated, are not directly 
understandable. 
It is essential in each radiotherapy center, to drive an investigation on 
geometric and dosimetric tolerances. All different accelerators have 
specific elements that generate and control the photon beams. The 
ionization chamber is at the heart of the device because it is the 
source of information used by the electronics and computer to control 
the beam. Several coils provide manipulation of the electron beam 
before the target. All these elements may vary during voluntary 
adjustments or drifts (age, breakdowns). However, possible variations 
are limited  by the computers. Some interlocks protect from 
unacceptable drift. Thus, the tolerances must at least be evaluated 
within these variations accepted by the manufacturer. 
To obtain tolerances, it is first necessary to assess physically the 
consequences of setting changes on profiles. Then, their impact on 
clinical irradiations have to be analyzed. When a dosimetric variation 
appear unacceptable, the corresponding beam variation help to define 
the tolerable limit. 
Conclusion: The technical evolutions of irradiations leads to 
important modulations with high dose rates for small targets. It is 
essential to establish, in each center, all geometric and dosimetric 
tolerances related to the use of FFF beams. 
 
 SYMPOSIUM: THE GENERATION OF NEW IMAGING 
MODALITIES: NEW PERSPECTIVES  
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Individualized medicine requires techniques that enable visualisation, 
quantification and time series of disease processes in a non-invasive 
way in individual patients. Medical imaging is intuitively very suitable 
for this purpose. Over the past decades, medical imaging has 
progressed in four distinct ways allowing quantitative imaging: 
innovations in medical devices (hardware), innovations in imaging 
agents, standardisation in imaging protocols, and innovations in 
imaging analysis. By these we have witnessed medical imaging in 
clinical oncology evolving from a primarily diagnostic tool to a 
theragnostic tool by a multitude of techniques involved in the 
treatment and characterisation of tumours and normal organs and 
tissues. Radiation oncology relies heavily on imaging. Computed 
tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI) are routinely used, mainly for dose 
calculation (CT) and target volume definition (CT, PET andMRI). 
However, much more can be gained by incorporating functional and 
molecular imaging in the processes of radiation oncology. First, 
imaging can play a major role in identifying interpatient differences 
by assessing the tumour phenotype. An example of this is Radiomics, a 
research field where the imaging data is converted in minable data 
thereby quantifying the tumour phenome. This information cannot 
only be used to select patient specific treatment, but also select for 
further imaging testing,e.g. hypoxia imaging or drug uptake imaging. 
Secondly, imaging plays a role by assessing intra-tumour and intra-
organ heterogeneity. Additional radiation dose must be delivered to 
those parts of the tumour that need it the most, e.g. because of 
increased biologic treatment resistance or reduced therapeutic drug 
uptake, and away from regions inside the lung that are most prone to 
complication. In this presentation we will focus on our work in these 
areas, on extracting more meaningful information from medical 
imaging, in the context of personalized medicine. 
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Magnetic resonance imaging (MRI) offers the potential for better 
tumour localisation, staging and monitoring therapy response 
compared to X-ray CT, due primarily to its inherently superior soft-
tissue contrast resolution. However, problems persist with the 
exclusive use of conventional MRI techniques in therapy planning in 
many body areas, while technical factors (such as image geometric 
distortion and artefacts) also pose problems.  As MRI technology 
continues to evolve, advances such as higher magnetic field strength 
systems, phased array detector coils allowing for fast image 
acquisitions, and multi-transmit technology, are improving the quality 
and robustness of several existing and novel MRI techniques, which 
will impact on radiotherapy planning and follow-up monitoring. 
In addition to conventional high resolution T1 / T2weighted imaging, 
the functional techniques of diffusion weighted imaging (DWI), whole-
body DWI, dynamic contrast enhanced (DCE), dynamic susceptibility 
contrast (DSC) and spectroscopic imaging have all benefited from the 
increased signal arising from high field MRI systems, while emerging 
techniques such as phosphorous spectroscopy and sodium imaging also 
show considerable potential. 
This talk will give a brief overview of MRI before delving into current 
high field MRI technology, explaining how these developments benefit 
both anatomical and functional MR imaging techniques.   
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With the evolution of new detector technologies and dual source CT 
scanners, dual energy CT examinations have become a clinical reality. 
The information of different x-ray spectra can be used to differentiate 
materials based on their specific absorptions. This approach can be 
clinically used to depict and to quantify iodine contrast agents. 
Moreover, postprocessing allows that beside normal appearing CT 
images (120 kVp equivalent) also virtual non-contrast images can be 
reconstructed, which helps to decrease the radiation exposure for 
multiphasic examinations because the pre-contrast scan can be 
omitted. Also reading 80 kVp images can add information because 
vessels or hypervascularized parenchymal lesions usually depict with 
much higher contrast. 
The lecture aims to introduce the basic principle of dual source dual 
energy applications in oncological patients. Moreover, clinical 
examples and results from the literature are presented with a focus 
on abdominal pathologies.  
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